Benefits Pro43m
Johnson & Johnson sues federal government over legality of plan to offer 340B rebates
Johnson & Johnson on Tuesday sued the Biden administration in a controversy over how it distributes rebates under the federal ...
JNJ's Phase 2 Study Of Nipocalimab Shows Improvement In Disease Activity In Sjögren's Disease
(RTTNews) - Johnson & Johnson (JNJ), Thursday announced results from additional analyses of the Phase 2 DAHLIAS study, evaluating the effects of Nipocalimab in participants with primary Sjogren's ...
Taiwan News2h
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study
Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
MassDevice17h
Johnson & Johnson MedTech inks distro deal to expand soft tissue solutions
Johnson & Johnson MedTech announced today that it entered into an exclusive commercial distribution agreement with Responsive Arthroscopy. The company agreed to a deal in the U.S. with Responsive ...
bovnews23h
Johnson & Johnson (JNJ) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...